|
| Effect of Maxing Shigan decoction on the IL-17 and TNF-α in children with mycoplasma pneumoniae pneumonia |
| Hits 1524 Download times 1204 Received:February 20, 2018 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2018.06.06 |
| Key Words
Maxing Shigan decoction;mycoplasma pneumoniae pneumonia;children;IL-17;TNF-α |
| Author Name | Affiliation | | WANG Zhihua | Pediatrics Department, Tianjin Integrated Traditional and Western Medicine and Nankai Hospital, Tianjin 300100, China | | SUN Jian | Pediatrics Department, Tianjin Integrated Traditional and Western Medicine and Nankai Hospital, Tianjin 300100, China | | LIU Yan | Pediatrics Department, Tianjin Integrated Traditional and Western Medicine and Nankai Hospital, Tianjin 300100, China | | WANG Xin | Pediatrics Department, Tianjin Integrated Traditional and Western Medicine and Nankai Hospital, Tianjin 300100, China | | WANG Yushui | Pediatrics Department, Tianjin Integrated Traditional and Western Medicine and Nankai Hospital, Tianjin 300100, China |
|
| Abstract
|
| [Objective] To observe the clinical efficacy for the treatment of mycoplasma pneumoniae pneumonia (MPP) children and the effect on myocardial enzymes by Maxing Shigan decoction (MXSGD).[Methods] The 61 patients were randomly divided into the treatment group and the control group. Two groups of patients were treated with intravenous infusion of azithromycin therapy for five days, treatment group was treated with MXSGD orally 7 days.Comprehensive efficacy and the myocardial enzyme values before and after treatment were compared between the two group to evaluate the clinical efficacy of MXSGD.[Results] The markedly effective rate of patients between treatment group and control group was respectively 67.7% and 36.7%,whereas, the total effective rate of patients between two groups was respectively 96.8% and 90.0%,there was significant difference between the two groups (P<0.05). The clinical symptoms of patients recovered significantly better in treatment group than in control group. In addition, compared with those in control group, patients in treatment group had fewer the side effects of medicine. The levels of IL-17 and TNF-α in children with MP pneumonia between two group were significantly lower after treatment than before treatment, there was significant difference (P<0.05). Furthermore, compared with those in control group, the levels of IL-17 and TNF-α in treatment group were significantly lower, there was significant difference between the two groups (P<0.05).[Conclusion] MXSGD combined with Western medicine can improve clinical symptoms and increase the total effective rate and cure rate of the children with MP pneumonia. In addition, MXSGD showed immunomodulating effect on IL-17 and TNF-α. |
|
|
|
|
|
|
|
